FDA Issues Letter to Evolus Over Jeuveau Social Media Promotion
The FDA’s Office of Prescription Drug Promotion has issued an untitled letter to Evolus, citing an Instagram promotional reel for Jeuveau (prabotulinumtoxinA-xvfs) that the agency says was false or misleading and minimized the risks associated with the prescription neurotoxin.
According to the FDA, the social media post improperly suggested that Jeuveau could be viewed similarly to an everyday beauty product. The agency objected to promotional language describing Evolus as “blurring the lines between what’s found in your beauty bag and what happens in the treatment room,” accompanied by syringe and lipstick emojis. FDA regulators stated that the message implied Jeuveau could be incorporated into a beauty routine like a cosmetic product, despite being a prescription drug that carries a boxed warning.
The agency said the promotion minimized the risks associated with Jeuveau by comparing it to consumer cosmetics and failing to adequately communicate important safety information. FDA described the implication as “especially problematic” because of the product’s boxed warning and other serious risks.
The letter also challenged claims regarding the drug’s effectiveness and onset of action. In the promotional reel, a patient described “getting rid of my lines” and commented on how quickly the treatment was working. The accompanying caption stated, “Lines today. Blurred in as little as 2 days.”
FDA said those statements overstated the drug’s benefits and created a misleading impression about treatment outcomes. Jeuveau is approved for the temporary improvement of moderate-to-severe glabellar lines, commonly known as frown lines, and not for eliminating them entirely. The agency also noted that the two-day onset claim relied on an exploratory study endpoint, while the pivotal clinical program’s primary efficacy endpoint was assessed at Day 30. According to FDA, the limitations of the exploratory endpoint make it difficult to draw reliable conclusions about the speed of onset represented in the advertisement.
The agency gave Evolus 15 working days to respond and explain how it plans to discontinue the promotional materials or otherwise address the concerns identified in the letter.
